Following the announcement of the Johnson and Johnson JNJ $1.75 billion cash deal for privately held Alios BioPharma, shares of competitor Achillion Pharmaceuticals ACHN are trading lower today.
Wells Fargo analyst Brian Abrahams notes that the Alios deal likely reduces interest in Achillion as a takeover target by Johnson and Johnson, citing similarities in the Alios and Achillion drug pipelines.
Deutsche Bank analyst Alethia Young, however, came to the defense and reiterated a Buy rating on ACHN this morning, saying that the firm still views Achillion as an important strategic asset, especially given that the Alios program is far away commercially even if it moves into clinical trial.
Shares of ACHN are trading down 5.83 percent at 10.18
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in